• Home
  • Contact
  • Search

Search form

  • Competences
  • Platforms
    • Antibiotics
    • Biocatalysis and Biosynthesis
    • Bioresource Technologies
    • In Vitro Diagnostics
    • Single-Use-Technology
    • TEDD Tissue Engineering for DD
    • Training for Pharma/Biotech
    • Translational and Clinical Bio-Manufacturing
  • Research and Development
    • Projects
    • Working with the Network
  • Services
    • Consulting Services
    • Working with the Network
  • Organisation
    • Members
    • Associated Members
    • Advisory Council
    • Joining the network
    • History
    • Organigramm
    • Forms
  • Events/News
    • Events
    • News
      • 24th October 2019 TEDD Annual Meeting 2019: Cell Sources and Stem Cell Generation for Drug Development
    • Galleries
  • Events
  • News
    • 24th October 2019 TEDD Annual Meeting 2019: Cell Sources and Stem Cell Generation for Drug Development
  • Galleries

biotechnet newsletter

Stay informed on our latest news!

24th October 2019 TEDD Annual Meeting 2019: Cell Sources and Stem Cell Generation for Drug Development

Primary and stem cells are becoming important sources for the generation of organotypic tissue models used in many biopharmaceutical applications, regenerative medicine, disease modelling and drug discovery. They promise to revolutionize the drug discovery process at all stages, from target identification through to toxicology studies.

While primary cells by nature represent the native tissue most accurately, they usually have limited capacity to divide and thus need to be freshly isolated for each assay limiting their application. In contrast the ability of stem cells to generate physiologically relevant cells in limitless supply makes them an attractive alternative to currently used recombinant cell lines or primary cells. Emerging technologies involve the production of organoids from human pluripotent stem cells (hPSCs) and the use of organ-on-a-chip devices. These approaches are showing great promise for developing a more reliable, rapid and cost-effective process when compared with the current use of animal models.

The current challenges include routinely directing stem cell differentiation to reproducibly and cost-effectively generate pure specific lineages. 

During TEDD Annual Meeting, we will discuss how stem cells have already been used in the drug discovery process and how novel technologies can be applied to attain widespread adoption of stem cell technology by the pharmaceutical and biotech industry.

PDF icon 2019_tedd_annual_meeting.pdf
  • Events
  • News
    • 24th October 2019 TEDD Annual Meeting 2019: Cell Sources and Stem Cell Generation for Drug Development
  • Galleries

biotechnet newsletter

Stay informed on our latest news!

© 2016 biotechnet Switzerland
  • Impressum
  • Login